Rinucumab

Rinucumab is a monoclonal antibody designed for the treatment of age-related macular degeneration (AMD). It was developed by Regeneron Pharmaceuticals and Bayer. Rinucumab works by inhibiting the action of platelet-derived growth factor (PDGF), which is believed to contribute to the development of AMD.

History

Rinucumab was first developed by Regeneron Pharmaceuticals and Bayer. In 2016, the companies announced that a Phase II study of the drug had failed to meet its primary endpoint. The study was designed to evaluate the efficacy and safety of rinucumab when used in combination with aflibercept, another drug developed by Regeneron and Bayer for the treatment of AMD.

Mechanism of Action

Rinucumab is a monoclonal antibody that targets and inhibits the action of PDGF. PDGF is a protein that promotes the growth of blood vessels, including those that contribute to the development of AMD. By inhibiting PDGF, rinucumab is believed to slow the progression of AMD.

Clinical Trials

In 2016, a Phase II clinical trial of rinucumab was conducted. The trial involved patients with AMD who were treated with a combination of rinucumab and aflibercept. However, the trial failed to meet its primary endpoint, which was to improve visual acuity in the patients.

Future Development

Following the failure of the Phase II trial, the future development of rinucumab is uncertain. Regeneron and Bayer have not announced any plans to continue the development of the drug.

See Also

• Monoclonal antibodies
• Age-related macular degeneration
• Platelet-derived growth factor
• Regeneron Pharmaceuticals
• Bayer